Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 502 clinical trials
Tumor Electric Fields Treatment System for Glioblastoma

This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.

recurrent glioblastoma
recurrent tumor
glioblastoma multiforme
  • 0 views
  • 19 Feb, 2024
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)

The primary purpose of this study is to determine whether adding SurVaxM to standard chemotherapy with temozolomide is better than treatment with temozolomide alone for patients with newly diagnosed glioblastoma. This study is designed to compare the duration of survival in patients with newly diagnosed glioblastoma receiving temozolomide plus SurVaxM …

  • 0 views
  • 02 Dec, 2024
  • 10 locations
Restrictive Use of Dexamethasone in Glioblastoma

The administration of steroids, most commonly dexamethasone (DEX), has established as standard of care during treatment of glioblastoma (GBM) and is widely used during the entire course of the disease including pre- and postoperative management, chemo- and radiotherapy.

neurologic symptoms
dexamethasone
immunosuppression
glioblastoma multiforme
  • 0 views
  • 19 Feb, 2024
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

triamcinolone
tumor treating fields therapy
topical agents
glioblastoma multiforme
triamcinolone topical
  • 0 views
  • 19 Feb, 2024
Niraparib/TTFields in GBM

Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).

niraparib
MRI
tumor treating fields therapy
glioblastoma multiforme
glioblastoma
  • 0 views
  • 19 Feb, 2024
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Background Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor. Researchers think that the drug selinexor, when combined with chemotherapy and radiation, might help.

blood test
neutrophil count
blood transfusion
therapeutic agent
cancer
  • 0 views
  • 19 Feb, 2024
Infigratinib in Recurrent Glioblastoma Patients

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed …

direct bilirubin
measurable disease
neutrophil count
local pathology review
fgfr3 k650e
  • 0 views
  • 19 Feb, 2024
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

This trial studies whether a customized video intervention can help to reduce anxiety in brain cancer patients undergoing radiation treatment and their caregivers. A customized neuro-imaging referenced symptom video that describes symptoms and side effects specific to the patients' tumor may result in an early and sustained reduction in anxiety …

MRI
psychiatric symptoms
cancer
brain tumor
glioblastoma multiforme
  • 0 views
  • 19 Feb, 2024
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-na ve GBM Patients.

A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-nave patients after resection of glioblastoma.

glioma
blood cell count
ejection fraction
temozolomide
glioblastoma multiforme
  • 0 views
  • 19 Feb, 2024
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease.

  • 0 views
  • 19 Feb, 2024